Neurovascular Thrombus Management

Showing all 3 results

Neurological Devices Market Size, Share & COVID-19 Impact Analysis | United States | 2022-2028 | MedSuite | Includes: Neurovascular Catheters, Neuromodulation Devices, and 12 more

iData’s U.S. neurology devices market MedSuite covers 14 markets and COVID-19 impacts. The MedSuite is a compilation of all reports related to a specific market. It is ideal for device manufacturers, product managers, marketing managers, and consultants looking for a detailed analysis of every market segment and sub-segment within a given market.


Neurological Devices Market Size, Share & COVID-19 Analysis | Europe | 2023-2029 | MedSuite | Includes: Ultrasonic Aspirator Market, Neurovascular Guidewires Market, and 12 more

The full report suite on the European market for neurological devices includes cerebrospinal fluid management devices, detachable coils, liquid embolics, neurovascular guidewires, neurovascular catheters, neurovascular stents, aneurysm clips, balloon occlusion devices, neurovascular thrombectomy devices, ultrasonic aspirators, neuromodulation devices, intrathecal pumps, stereotactic devices and transcranial magnetic simulators.


Mechanical Thrombectomy Devices Market Analysis | United States | 2020-2026 | MedCore

Ischemic Stroke is caused by an obstruction within a blood vessel that is supplying blood to the brain. This is often caused by blood clots but can also be caused by other substances like plaque. The gold standard treatment for strokes for many years has been the administration of clot dissolving or clot busting medication called tissue plasminogen activator (tPA). This type of drug must be administered as soon as possible, with a four hour window from symptom onset, to increase chances of recovery. A significant number of patients do not get to healthcare facilities quickly enough to meet that window and even some of those who do, later experience hemorrhagic complications from the medication. It is very effective for smaller clots but often fails to break up larger clots. Some patients cannot receive tPA, in which cases physicians rely on antiplatelet or anticoagulant medicine to ensure blood clots do not get larger.